Component

Mouse LPC-model demyelination volume

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The SA-treated LPC groups showed less demyelination at day 14.

    Shikimic acid → Mouse LPC-model demyelination volume source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.
    experimental_contrast
    {"intervention": "SA after LPC challenge", "comparator": "Vehicle after LPC challenge", "endpoint": "The SA-treated LPC groups showed less demyelination at day 14.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Repair-time distinction, not proof of protection from initial injury or human MS efficacy.
    plain_language
    The SA-treated LPC groups showed less demyelination at day 14.
    primary_references
    Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice. | 2019 | DOI 10.1007/s12264-018-0322-7 | PMID 30684125 | https://pubmed.ncbi.nlm.nih.gov/30684125/ | https://doi.org/10.1007/s12264-018-0322-7 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6527532/
    source_locator
    Reviewed reference lines 73-73; exact primary location described in quoted passage where extracted.

    Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 73–73

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology. · source_derived_draft · unverified_draft

    **Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)
    Complete structured claim and evidence

  2. The SA-treated LPC groups showed no significant reduction at day 7.

    Shikimic acid → Mouse LPC-model demyelination volume source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.
    experimental_contrast
    {"intervention": "SA after LPC challenge", "comparator": "Vehicle after LPC challenge", "endpoint": "The SA-treated LPC groups showed no significant reduction at day 7.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Repair-time distinction, not proof of protection from initial injury or human MS efficacy.
    plain_language
    The SA-treated LPC groups showed no significant reduction at day 7.
    primary_references
    Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice. | 2019 | DOI 10.1007/s12264-018-0322-7 | PMID 30684125 | https://pubmed.ncbi.nlm.nih.gov/30684125/ | https://doi.org/10.1007/s12264-018-0322-7 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6527532/
    source_locator
    Reviewed reference lines 73-73; exact primary location described in quoted passage where extracted.

    Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 73–73

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse focal LPC demyelination; 100–200 mg/kg SA groups; day-specific histology. · source_derived_draft · unverified_draft

    **Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.